TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05684159: A Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Sponsor: NovelMed Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$929,600

Rescue Site Savings

+$597,600

Unlock Full NCT05684159 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05684159 Rescue Dossier →